good buy stocks

Back in October 2016, the Federal Communications Commission (FCC) imposed privacy rules that required Internet and mobile phone corporations to get consent from their customers before sharing personal data with advertisers.

But yesterday (March 28) — amid news of the Russian spy scandal, the failed healthcare vote, the Gorsuch hearing, and more — the House voted to repeal these rules.

Now the provisions are waiting to be signed into law by the president.

When passed, it means the likes of Comcast Corp. (Nasdaq: CMCSA) — an ISP that’s made our “most hated companies” list for three years straight — will immediately begin to spy on you, selling to the highest bidder your:

Location Financial information Health information Web browsing history

Verizon Communications Inc. (NYSE: VZ) and AT&T Inc. (NYSE: T), as well as any other company that provides Internet or mobile phone services in the United States, would be alongside Comcast in the spy game. Each will be greenlighted to track, gather, use, and sell your data to third-party companies.

good buy stocks: Mastercard Incorporated(MA)

Advisors’ Opinion:

  • [By Matthew Cochrane]

    Keeping these statistics in mind, one can see how marrying these two concepts would be equivalent to finding the Holy Grail of payments. This is how Mastercard Inc (NYSE:MA), clearly one of the giants in the payments space, plans to capture market share and win more card issuer deals by making payments as safe and frictionless as possible.

  • [By John Ballard]

    Partnerships play a crucial role in extending PayPal’s reach to new customers and driving higher engagement. The deal with Visa(NYSE:V) opened the door for partnerships with Mastercard(NYSE:MA), Citigroup(NYSE:C), and Fidelity National Information Services (NYSE:FIS). As a result, more deals will come that will increase PayPal’s relevancy and ubiquity in the mobile payment landscape.


    Visas not alone when it comes to being a dividend miser. Rival MasterCard Inc (MA) is every bit as bad.

    MasterCards dividend payout ratio is an extremely low 21%, and its dividend yield is a pitiful 0.8%. I suppose that might be competitive with a savings account these days. But its less than half the dividend yield of the S&P 500, and theres just no excuse for that.

good buy stocks: Sanofi(SNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hopes were high for MannKind (MNKD) when its inhaled insulin Afrezza was approved by the FDA more than two years ago. At the time, Barron’s warned that it was time to dump MannKind’s shares, something that now seems prescient, as its shares have since tumbled 95%. No wonder, as the news since then has been far from good. MannKind found a partner in Sanofi (SNY), only to get dumped in early 2016, and has since been forced to sell property to raise cash. And now MannKind could be on the verge of being delisted from the Nasdaq due to its sub $1 stock price. What now? Piper Jaffray’sJoshua Schimmer and team see a reverse stock split in MannKind’s future:

  • [By Brian Feroldi]

    Shares of Flexion Therapeutics (NASDAQ:FLXN) rose by more than 33% at$26.28 in Thursday trading, in response to rumors that a takeover bid from Sanofi (NYSE:SNY) is looming.

  • [By Sean Williams]

    MannKind has just one Food and Drug Administration-approved therapy, an inhalable type 1 and type 2 diabetes drug known as Afrezza. On paper Afrezza looked like a winner. It was fast-acting, it metabolized through the body more quickly than traditional insulin, and it was exceptionally convenient since there were no needles involved. The company also wound up licensing the drug out to Sanofi (NYSE:SNY) in 2014, netting much needed upfront capital and help on the expenses front.

  • [By Brian Orelli]

    Image source: Getty Images.

    What happened with Alnylam Pharmaceuticals this quarter? All of the biotech’s revenue comes from its partners. The upfront payments are often amortized over many years, so the jump in revenue is nothing to get excited about. The big news during the quarter was the decision to stop development of revusiran after a phase 3 trial in patients with ATTR amyloidosis showed more patients taking revusiran died than those taking placebo. APOLLO, a phase 3 trial testing patisiran in patients with polyneuropathy due to hereditary ATTR amyloidosis, is due to read out in the middle of this year, hopefully leading to a marketing application filed with the FDA by the end of the year. Data presented for its hemophilia and other bleeding disorders drug, fitusiran, were positive, leading partner Sanofi (NYSE:SNY) to exercise its right to co-develop and co-promote fitusiran with Alnylam in the U.S., Canada, and Western Europe. Sanofi already had commercial rights to the rest of the world. The duo plans to start a phase 3 program for fitusiran in early 2017. The Medicines Company (NASDAQ:MDCO) presented more positive data for their cholesterol-lowering drug inclisiran, which was called ALN-PCSsc before Alnylam out-licensed the drug. The Medicines Company is running a new phase 2 trial in patients with a genetic disease that causes extremely high levels of cholesterol, and plans to start a phase 3 program in the middle of this year. What management had to say

    The APOLLO results, combined with starting phase 3 trials for fitusiran and inclisiran, puts Alnylam in a good position for years to come. CEO John Maraganore explained: “This potentially positions Alnylam to have a steady flow of phase 3 readouts, and if positive, commercial launches on essentially an annual basis going forward.”

good buy stocks: Peregrine Pharmaceuticals Inc.(PPHM)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

good buy stocks: Liquidity Services Inc.(LQDT)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Liquidity Service (LQDT) is an online auction marketplace for surplus and salvage assets. This stock closed up 14.9% at $34.44 in Monday’s trading session.

    Monday’s Volume: 1.60 million

    Three-Month Average Volume: 402,622

    Volume % Change: 336%

    From a technical perspective, LQDT skyrocketed higher here right off its 50-day moving average of $30.94 with strong upside volume. This move briefly saw shares of LQDT trend back above its 200-day moving average at $34.60, before it closed just below that level at $34.44. Shares of LQDT are now quickly moving within range of triggering a big breakout trade. That trade will hit if LQDT manages to take out Monday’s intraday high of $35.21 and then once it clears some more near-term overhead resistance at $35.71 with high volume.

    Traders should now look for long-biased trades in LQDT as long as it’s trending above $32.67 or above $31.60 and then once it sustains a move or close above those breakout levels with volume that hits near or above 402,622 shares. If we get that breakout soon, then LQDT will set up to re-test or possibly take out its next major overhead resistance levels at $38 to $40.90.

  • [By Jon C. Ogg]

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

good buy stocks: Karyopharm Therapeutics Inc.(KPTI)

Advisors’ Opinion:

  • [By Chris Lange]

    Karyopharm Therapeutics Inc. (NASDAQ: KPTI) was raised to a Buy rating from Hold, and the price target was increased to $12 from $9, at Jefferies. The firm said its call is based on its future revenue opportunity in multiple myeloma. Itsshares most recently closed at $10.62, with a consensus price target of $16.30 and a 52-week range of $4.83 to $19.41.

Leave a Reply

Your email address will not be published. Required fields are marked *